Foscenvivint

Clinical data

Other namesPRI 724; OP 724

Legal status

Legal statusInvestigational

Identifiers

IUPAC name [4-[[(6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate

PubChem CID

Chemical and physical data

FormulaC33H35N6O7P

Molar mass658.652 g·mol−1

3D model (JSmol)

SMILES C[C@H]1[C@H]2N([C@H](C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C

InChI InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1Key:VHOZWHQPEJGPCC-AZXNYEMZSA-N

Foscenvivint (PRI 724 or OP 724) is a CREB-binding protein/β-catenin inhibitor that is developed for the treatment of liver diseases such as primary biliary cholangitis, hepatocellular carcinoma, and hepatitis C and B virus-induced liver cirrhosis.